Inve India ▾

Nath Bio-Genes (India) share price & results

Nath Bio-Genes (India) Limited· Fast Moving Consumer Goods

Results to
Jun 2026
Latest analysed call
Q4 FY26
Ownership as of
Jun 2026

Indian hybrid-seed producer of cotton, paddy, maize and vegetable seeds, plus plant-nutrition products, sold through a pan-India distributor network.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue323 ₹ crore+15.4% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin11.0 %0.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit33.0 ₹ crore+13.8% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity5.17 %−0.8 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-3.58 %−7.4 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)20.99 %+58.0 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

1 of 4 judged targets kept · 4 open · verdicts reflect calls analysed to Q4 FY26.

Nath Bio-Genes (India) Limited management guidance track record on Inve: 8 targets tracked across analysed earnings calls (1 achieved, 3 missed, 4 open).

TargetOriginal wordingSaidLatest callVerdict
Revenue Growth15% revenue growth for this year (FY26)
Call transcript, Q4 FY25 · 30 Apr 2025		Q4 FY25Q4 FY26:Achieved. Full year FY26 revenue grew 19% YoY to INR 431.6 crores, exceeding the 15% target.
Call transcript, Q4 FY26 · 5 May 2026		Achieved
EBITDA/PBT MarginIncrease about 2 to 3 basis points
Call transcript, Q4 FY25 · 30 Apr 2025		Q4 FY25Q4 FY26:Missed. Gross margin compressed to 56% from 63% in FY25. EBITDA margin for FY26 was 12%, and PAT margin fell to 9%. Management attributed the drop to higher finance and marketing costs.
Call transcript, Q4 FY26 · 5 May 2026		Missed
Total SalesCross INR 500 crores in a year or 2
Call transcript, Q4 FY25 · 30 Apr 2025		Q4 FY25Q4 FY26:FY26 sales were INR 431.6 crores, crossing the INR 400 crore prerequisite mentioned in Q2. Management reiterated the goal, stating they 'hope to cross INR 500 crores of top line soon.'
Call transcript, Q4 FY26 · 5 May 2026		On Track

Source: Inve Guidance Tracker for Nath Bio-Genes (India) Limited · to Q4 FY26

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

3 of Nath Bio-Genes (India) Limited's 8 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 5 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹133.42 +2.45% · +₹3.19

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −21.6% 1Y

₹140₹160₹180₹200Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 14 Nov 2025Q4 FY26 — 5 May 2026

1Y: ₹170.13 on 24 Oct 2025 → ₹133.42. High ₹196.01 (30 Apr 2026), low ₹129.02 (30 Mar 2026).

Previous close
₹130.23
Market cap
₹252 Cr
52-week range
₹129.02 – ₹196.01
One year
−21.39%
Price to earnings (TTM to Jun 2026)
7.37×
Return on equity (TTM to Jun 2026)
5.17%

Overview

Symbol
NSE:NATHBIOGEN
Exchange
NSE
Currency
INR

What Nath Bio-Genes (India) Limited does

Based on the company's own presentations, annual report and earnings calls.

Nath Bio-Genes researches, breeds and produces hybrid seeds for field crops (cotton, paddy, wheat, maize, bajra) and vegetables (tomato, chili, cucumber, okra) under brand names such as Sanket, Jumbo, Super-27 and Akhand, sold to farmers via a network of distributors and dealers. It also makes plant-nutrition/bio-stimulant products (Win-Chi-Win, Windrow GOLii, Winhall Granules) for soil health and productivity. The company is extending its reach internationally through a joint venture in Uzbekistan and regulatory approval efforts for commercial sales in the Philippines.

Segments

  • Field Crops
  • Vegetables
  • Plant Nutrition
  • International
Distributor & dealer network
~20,000
Branch offices
17
Processing plants
10
States covered
23
Cold storage, warehouse & conditioning godown capacity
25,000 MT
R&D infrastructure
DSIR-recognized R&D innovation centres
Headquarters Chhatrapati Sambhajinagar (Aurangabad), Maharashtra

How the price took the results

close before → close after

Q4 FY26
−8.4%
5 May
Q2 FY26
+1.3%
14 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Nath Bio-Genes (India) Limited

Free account: one company. Everything above stays public.

Write why you follow Nath Bio-Genes (India) Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Fast Moving Consumer Goods companies

All Fast Moving Consumer Goods companies → · Fast Moving Consumer Goods earnings growth →

Learn to analyse Nath Bio-Genes (India) Limited

Guides on how to read this kind of business and the numbers that matter.